Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Ludwig-Maximilians-Universitat München

Ludwig-maximalians-universitat Munchen

Georg-august-universität Göttingen

Modag Gmbh

Armin Giese

Christian Griesinger

Andrei Leonov

Sergey Ryazanov

Thomas Hirschberger

Markus Geissen

Jens Wagner

Martin H Groschup

Uwe Bertsch

Hans Kretzschmar

Matthias Habeck

Paul Tavan

Thomas M Jovin

Margarete Schön

Petra Frick Née Weber

Felix Schmidt

Petra Frick

Tiago F Outeiro

Diana F Lazaro

Dorothea Becker

Michael P Schön

Mathias Habeck

Daniel Weckbecker

Bernd Pichler

Sabrina Buss

Laura Kubler

Kristina Herfert

Andreas Maurer

The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma. 

Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma

The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases

The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD).  The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.

Water-soluble derivatives of 3,5-diphenyl-diazole compounds

Growing community of inventors

Munich, Germany

Armin Giese